| | Peptide receptors | Receptor subtypes | Expressing tumor type | Targeting agents |
| | Somatostatin | sst1, sst2, sst3, sst4, and sst5 | GH-producing pituitary adenoma, paraganglioma, nonfunctioning pituitary adenoma, pheochromocytomas | Radioisotopes, AN-201 (a potent cytotoxic radical 2-pyrrolinodoxorubicin), doxorubicin | | Pituitary adenylate cyclase activating peptide (PACAP) | PAC1 | Pheochromocytomas
and paragangliomas | Radioisotopes, doxorubicin | | Vasoactive intestinal peptide (VIP/PACAP) | VPAC1, VPAC2 | Cancers of lung
stomach, colon, rectum, breast, prostate, pancreatic ducts,
liver, and urinary bladder | Radioisotopes, camptothecin | | Cholecystokinin (CCK) | CCK1 (formerly CCK-A) and CCK2 | Small cell lung cancers, medullary
thyroid carcinomas, astrocytomas, and ovarian cancers | Radioisotopes, cisplatin | | Bombesin/gastrin-releasing peptide (GRP) | BB1, GRP receptor subtype (BB2), the BB3 and BB4 | Renal cell, breast, and
prostate carcinomas | Doxorubicin, 2-pyrrolinodoxorubicin | | Neurotensin | NTR1, NTR2, NTR3 | Small cell lung cancer, neuroblastoma,
pancreatic and colonic cancer | Radioisotopes | | Substance P | NK1 receptor | Glial tumors | Radioisotopes | | Neuropeptide Y | Y1–Y6 | Breast carcinomas | Radioisotopes |
|
|
